Načítá se...
LRRK2 G2019S Mutations are associated with an increased cancer risk in Parkinson Disease
Leucine rich repeat kinase (LRRK2) G2019S mutations are presumed to cause PD through a toxic gain of function of the protein kinase. Small molecule kinase inhibitors have been developed for the treatment of certain cancers, and some antioncogenic agents such as sunitinib, may non-specifically inhibi...
Uloženo v:
| Hlavní autoři: | , , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2010
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2978749/ https://ncbi.nlm.nih.gov/pubmed/20818610 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mds.23314 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|